All News

Glecaprevir/pibrentasvir found to be effective in clinical trials treating patients with hepatitis C virus also being treated for opioid substitution therapy.

Ongoing access to diabetes self-management education and support, and promoting good medication adherence are among the keys to managing high blood glucose in patients with type 2 diabetes.

Specialty medications are still mostly branded products, but patients remain hesitant to accept less expensive generic alternatives when the option is available.

Stigma surrounding mental illnesses can prevent people from seeking treatment.

The study points to the importance of screening for and treating arthritis-related pain in older adults with varying degrees of depression.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Millennials, Generation X, and Baby Boomers all have different health care needs.

Siponimod is an oral, once-daily medication for the treatment of multiple sclerosis in adults.

What's in a name? That which we call epinephrine by any other name would still be epinephrine.

Inotersen (Tegsedi) once-weekly subcutaneous injection is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Survey data reveal rates of diabetes prevalence by subtype among adults.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Officials with the National Community Pharmacists Association called the opioid relief package that is awaiting President Trump's signature "vital."

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

Officials with the FDA have approved a supplemental application for Merck's Gardasil 9 that expands the approved use of the HPV vaccine to include women and men aged 27 to 45 years

The FDA has approved Akcea Therapeutics' inotersen (Tegsedi), an antisense oligonucleotide that inhibits the production of the transthyretin protein (amyloid), for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Although their use is sometimes necessary, overprescribing the bacteria-killing drugs can be dangerous.

The Pharmacy Quality Alliance has praised the bipartisan efforts of Congress in passing the SUPPORT for Patients and Communities Act (HR 6).

A program that provides pre-exposure prophylaxis to those at high risk of the infection is feasible and could help lower incidences, according to a study being presented at ID Week.

Clinical trial data show results from switching to Delstrigo from other antiretroviral treatments for HIV.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.

Top news of the week from Specialty Pharmacy Times.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.

Emicizumab-kxwh (Hemlibra) is now the only prophylactic treatment approved for individuals with hemophilia A with and without factor VIII inhibitors.

Officials with the FDA have approved emicizumab-kxwh (Hemlibra, Genentech) for routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors.

Emicizumab-kxwh (Hemlibra) is now the only FDA-approved treatment for hemophilia A with and without factor VIII inhibitors.